Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Compare

1,462 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OCUL Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Ocular

Therapeutix

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OCUL Stock 12 Month Forecast

Average Price Target

$20.83

▲(80.66% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $20.83 with a high forecast of $31.00 and a low forecast of $14.00. The average price target represents a 80.66% change from the last price of $11.53.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","32":"$32","11.75":"$11.75","18.5":"$18.5","25.25":"$25.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,11.75,18.5,25.25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,12.575384615384614,14.110769230769229,15.646153846153846,17.18153846153846,18.716923076923074,20.252307692307692,21.787692307692307,23.323076923076922,24.858461538461537,26.39384615384615,27.929230769230767,29.464615384615385,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,11.793076923076923,12.546153846153846,13.299230769230768,14.052307692307691,14.805384615384614,15.558461538461536,16.31153846153846,17.064615384615383,17.817692307692305,18.57076923076923,19.32384615384615,20.076923076923073,{"y":20.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,11.267692307692307,11.495384615384614,11.723076923076922,11.95076923076923,12.178461538461537,12.406153846153845,12.633846153846154,12.861538461538462,13.089230769230769,13.316923076923077,13.544615384615383,13.772307692307692,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$31.00

Average Price Target$20.83

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Biren Amin

Piper Sandler

$31

Buy

168.86%

Upside

Reiterated

10/23/25

Piper Sandler Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)

Yi Chen

H.C. Wainwright

$15→$19

Buy

64.79%

Upside

Reiterated

10/08/25

Ocular Therapeutix price target raised to $19 from $15 at H.C. WainwrightOcular Therapeutix price target raised to $19 from $15 at H.C. Wainwright

Colleen M. Kusy

Robert W. Baird

$17→$24

Buy

108.15%

Upside

Reiterated

10/03/25

Ocular Therapeutix price target raised to $24 from $17 at BairdOcular Therapeutix price target raised to $24 from $17 at Baird

Jonathan Wolleben

Citizens JMP

$20→$29

Buy

151.52%

Upside

Reiterated

10/01/25

Ocular Therapeutix price target raised to $29 from $20 at Citizens JMPOcular Therapeutix price target raised to $29 from $20 at Citizens JMP

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

10/01/25

Ocular Therapeutix's Strategic Initiatives and Clinical Advancements Drive Buy Rating9:37 AM Research | Healthcare Ocular Therapeutix, Inc. (OCUL) $11.69 Market Value (M): $2,034 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- Phase III Plans in DR It, as Ocular hosted an investor day in New York, where it provided updates on its ongoing SOL-1 and SOL-R studies of Axpaxli in wet AMD (wAMD), outlined the design of the SOL-X open-label extension study, introduced its plans for pivotal studies of Axpaxli in nonproliferative diabetic retinopathy (NPDR), and reviewed the commercial opportunity for Axpaxli in retinal vascular disorders.

Serge Belanger

Needham

$15→$20

Buy

73.46%

Upside

Reiterated

10/01/25

Ocular Therapeutix: Buy Rating Affirmed Amid Promising Clinical Advancements and Strong Financial Position

Lisa Walter

RBC Capital

$17

Buy

47.44%

Upside

Reiterated

10/01/25

RBC Capital Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)

Tazeen Ahmad

Bank of America Securities

$18

Buy

56.11%

Upside

Reiterated

10/01/25

Buy Rating for Ocular Therapeutix Driven by Strategic Advancements and Promising Clinical Trials in Diabetic Retinopathy

Daniil Gataulin

Chardan Capital

$21

Buy

82.13%

Upside

Initiated

09/15/25

Ocular Therapeutix initiated with a Buy at ChardanOcular Therapeutix initiated with a Buy at Chardan

Greg Harrison

Scotiabank

$22→$20

Buy

73.46%

Upside

Reiterated

08/06/25

Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)

William Maughan

Clear Street

$18

Buy

56.11%

Upside

Reiterated

08/05/25

Clear Street reiterates Buy Rating on Ocular Therapeutix (OCUL)Clear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Tara Bancroft

TD Cowen

$14

Buy

21.42%

Upside

Reiterated

08/05/25

TD Cowen on Ocular Therapeutix (OCUL): SOL-1 Data In Q1:2026 Should Be Positive And Clinically RelevantTD Cowen analyst Tara Bancroft reiterated a Buy rating and $14.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Dane Leone

Raymond James

$19

Buy

64.79%

Upside

Reiterated

08/04/25

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Biren Amin

Piper Sandler

$31

Buy

168.86%

Upside

Reiterated

10/23/25

Piper Sandler Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)

Yi Chen

H.C. Wainwright

$15→$19

Buy

64.79%

Upside

Reiterated

10/08/25

Ocular Therapeutix price target raised to $19 from $15 at H.C. WainwrightOcular Therapeutix price target raised to $19 from $15 at H.C. Wainwright

Colleen M. Kusy

Robert W. Baird

$17→$24

Buy

108.15%

Upside

Reiterated

10/03/25

Ocular Therapeutix price target raised to $24 from $17 at BairdOcular Therapeutix price target raised to $24 from $17 at Baird

Jonathan Wolleben

Citizens JMP

$20→$29

Buy

151.52%

Upside

Reiterated

10/01/25

Ocular Therapeutix price target raised to $29 from $20 at Citizens JMPOcular Therapeutix price target raised to $29 from $20 at Citizens JMP

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

10/01/25

Serge Belanger

Needham

$15→$20

Buy

73.46%

Upside

Reiterated

10/01/25

Ocular Therapeutix: Buy Rating Affirmed Amid Promising Clinical Advancements and Strong Financial Position

Lisa Walter

RBC Capital

$17

Buy

47.44%

Upside

Reiterated

10/01/25

RBC Capital Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)

Tazeen Ahmad

Bank of America Securities

$18

Buy

56.11%

Upside

Reiterated

10/01/25

Buy Rating for Ocular Therapeutix Driven by Strategic Advancements and Promising Clinical Trials in Diabetic Retinopathy

Daniil Gataulin

Chardan Capital

$21

Buy

82.13%

Upside

Initiated

09/15/25

Ocular Therapeutix initiated with a Buy at ChardanOcular Therapeutix initiated with a Buy at Chardan

Greg Harrison

Scotiabank

$22→$20

Buy

73.46%

Upside

Reiterated

08/06/25

Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)

William Maughan

Clear Street

$18

Buy

56.11%

Upside

Reiterated

08/05/25

Clear Street reiterates Buy Rating on Ocular Therapeutix (OCUL)Clear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Tara Bancroft

TD Cowen

$14

Buy

21.42%

Upside

Reiterated

08/05/25

Dane Leone

Raymond James

$19

Buy

64.79%

Upside

Reiterated

08/04/25

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

1 Month

xxx

Success Rate

15/32 ratings generated profit

Average Return

+5.35%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.88% of your transactions generating a profit, with an average return of +5.35% per trade.

3 Months

xxx

Success Rate

18/32 ratings generated profit

Average Return

+10.95%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +10.95% per trade.

1 Year

Yi ChenH.C. Wainwright

Success Rate

15/21 ratings generated profit

Average Return

+49.85%

reiterated a buy rating 22 days ago

Copying Yi Chen's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +49.85% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+98.02%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +98.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OCUL Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OCUL has received 19 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. OCUL average Analyst price target in the past 3 months is 20.83.

Each month's total comprises the sum of three months' worth of ratings.

OCUL Financial Forecast

OCUL Earnings Forecast

Next quarter’s earnings estimate for OCUL is -$0.37 with a range of -$0.41 to -$0.33. The previous quarter’s EPS was -$0.39. OCUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year OCUL has Preformed in-line its overall industry.

OCUL Sales Forecast

Next quarter’s sales forecast for OCUL is $14.63M with a range of $12.57M to $19.00M. The previous quarter’s sales results were $13.46M. OCUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year OCUL has Preformed in-line its overall industry.

OCUL Stock Forecast FAQ

What is OCUL’s average 12-month price target, according to analysts?

Based on analyst ratings, Ocular Therapeutix’s 12-month average price target is 20.83.

What is OCUL’s upside potential, based on the analysts’ average price target?

Ocular Therapeutix has 80.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OCUL a Buy, Sell or Hold?

Ocular Therapeutix has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ocular Therapeutix’s price target?

The average price target for Ocular Therapeutix is 20.83. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $31.00 ,the lowest forecast is $14.00. The average price target represents 80.66% Increase from the current price of $11.53.

What do analysts say about Ocular Therapeutix?

Ocular Therapeutix’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of OCUL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

OCUL Analyst Ratings

OCUL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ocular Therapeutix

OCUL Analyst Recommendation Trends

OCUL Financial Forecast

OCUL Earnings Forecast

OCUL Sales Forecast

OCUL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts